<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907374</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 04-09-772</org_study_id>
    <secondary_id>U54RR014616</secondary_id>
    <nct_id>NCT00907374</nct_id>
  </id_info>
  <brief_title>Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria</brief_title>
  <acronym>END-IT</acronym>
  <official_title>Early Nephropathy Study in Diabetes With Inhibitory Renin-Angiotensin-Aldosterone System Therapy (END-IT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Drew University of Medicine and Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charles Drew University of Medicine and Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the effect of standard versus aggressive inhibition
      of the renin-angiotensin system (RAS)in type 2 diabetic patients with microalbuminuria (MA)
      on; a)progression of microalbuminuria, b)estimated glomerular filtration rate (eGFR),
      c)endothelial dysfunction (measured by post-hyperemia arterial tonometry) and d)the slowing
      of the progression of atherosclerotic disease (measured by carotid intima media thickness
      [CIMT]).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic patients with confirmed MA (50-300 mg albumin per g creatinine) on a morning spot
      urine sample were entered into a one to three month run-in phase before randomization. (50
      mg/g was used as the lower limit to allow room for improvement to reach normal.) Since
      hypertension and uncontrolled hyperglycemia will cause MA, blood pressure (BP) and hemoglobin
      A1c (AIC) levels were reduced to &lt;130/80 mm Hg and &lt;8.0%, respectively, during this period.
      All patients had been on various doses of an angiotensin converting enzyme inhibitor (ACE-I)
      which were reduced to 10 mg benazepril and BP controlled with other classes of
      anti-hypertensive drugs (except for angiotensin receptor blockers [ARB's]). Glycemia was
      treated with intensification of their current therapy. MA and BP were measured monthly.

      When goal levels of BP and AIC were achieved and MA was still present, patients were
      randomized to either low dose RAS inhibition (10 mg benazepril) (Standard) or aggressive
      inhibition of the RAS (Aggressive). MA continued to be measured monthly and the progressive
      increase in doses of an ACE-I and an ARB was as follows. Benazepril (the ACE-I) - 10 mg to 20
      mg to 40 mg to adding losartan (the ARB) -25 mg to 50 mg to 100 mg to increasing benazepril
      to 80 mg with the goal of returning albumin excretion to normal. Other classes of drugs were
      reduced as necessary to keep systolic BP &gt; 100 mm Hg. Serum creatinine and potassium[K+] were
      measured monthly, AIC levels every 3 months and CIMT by ultrasound and endothelial function
      by post hyperemia and nitroglycerine (NTG) - induced peripheral artery tonometry (PAT) via
      finger plethysmography every six months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio</measure>
    <time_frame>3 to 36 months</time_frame>
    <description>Average of ratio for all participants during the 3-36 months of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated Glomerular Filtration Rate</measure>
    <time_frame>3 to 36 months</time_frame>
    <description>This is an average for all participants during the 3-36 month study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid Artery Intima Thickness</measure>
    <time_frame>6 to 36 months</time_frame>
    <description>Thickness of intima of right carotid artery; average of all particpants from 6-36 months of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Dysfunction</measure>
    <time_frame>6 to 36 months</time_frame>
    <description>Post hyperemia increase in blood flow - fold increase from before and after occluding BP; values are mean of all participants in 6-36 months of study period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Microalbuminuria</condition>
  <arm_group>
    <arm_group_label>Low dose inhibition of RAS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard low dose inhibition of the RAS with 10 mg of benazepril orally daily to treat microalbuminuria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Agressive inhibition of the RAS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40-80 mg benazepril plus 25-100 mg losartan both orally once or twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>benazepril</intervention_name>
    <description>benazepril 10 mg orally once daily</description>
    <arm_group_label>Low dose inhibition of RAS</arm_group_label>
    <other_name>Lotensin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>benazepril</intervention_name>
    <description>40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily</description>
    <arm_group_label>Agressive inhibition of the RAS</arm_group_label>
    <other_name>Lotensin</other_name>
    <other_name>Cozaar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, age 18-70

          -  Subjects with diabetic renal disease as defined by spot urine albumin - creatinine
             ratio 30-300mg/g and estimated glomerular filtration rate of &gt;60 ml/min

        Exclusion Criteria:

          -  Intake of non-steroidal anti-inflammatory agents (NSAIDs) more than 15 days/month,
             excluding aspirin.

          -  Inability to discontinue NSAIDs or aspirin for 5 days prior to GFR measurement.

          -  History of severe adverse reaction to any of the randomized drugs required for use in
             the protocol or contraindication of their use.

          -  Participation in another intervention study.

          -  Pregnancy or likelihood of becoming pregnant during the study period; lactation

          -  Clinical and laboratory evidence of any renal disease other than diabetic nephropathy.

          -  History of drug abuse in the past 2 years, including narcotics, cocaine or alcohol (&gt;
             21 drinks per week). Serious systemic disease that might influence survival or the
             course of renal disease. (Chronic oral steroid therapy is exclusion, but
             steroid-containing nasal sprays are not. Inactive sarcoidosis is not an exclusion).

          -  History of malignant or accelerated hypertension within 6 months prior to study entry;
             previous chronic peritoneal or hemodialysis or renal transplantation. Known secondary
             causes of hypertension. Spot urine albumin - creatinine ratio exceeding 300 (mg/g)

          -  Serum potassium level &gt; 5.5 mEq/L for those not on ACE inhibitors during Baseline, or
             serum potassium level &gt; 5.9 mEq/L for those on ACE inhibitors during Baseline.

        Leukopenia &lt; 2,500/mm3 at screening and confirmed at the end of Baseline.

          -  Doubt that the participant will be able to adhere to medications or comply with the
             protocol visit schedule

          -  Arm Circumference &gt; 52 cm, which precludes measuring blood pressure with the &quot;thigh&quot;
             blood pressure cuff. Arm length such that if the cuff circumference extended into the
             antecubital space so that the cuff interfered with placement of the stethoscope over
             the brachial artery for blood pressure measurement

          -  Clinical evidence of lead intoxication. Clinical evidence of congestive heart failure,
             current or within the preceding six months. Ejection fraction below 35% measured by
             any method. Heart block greater than first degree or any other arrhythmia that
             contraindicated the use of any of the primary BP drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naureen Taureen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles Drew University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mayer B. Davidson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Charles Drew University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles Drew University</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2009</study_first_posted>
  <results_first_submitted>February 9, 2012</results_first_submitted>
  <results_first_submitted_qc>March 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 30, 2012</results_first_posted>
  <last_update_submitted>March 28, 2012</last_update_submitted>
  <last_update_submitted_qc>March 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles Drew University of Medicine and Science</investigator_affiliation>
    <investigator_full_name>Mayer Davidson</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Microalbuminuria</keyword>
  <keyword>Carotid intima media thickness</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Renin angiotensin system</keyword>
  <keyword>Diabetic nephropathy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benazepril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>46 patients were enrolled and entered the run-in but 19 were not randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Inhibition of RAS</title>
          <description>10 mg benazepril plus other anti-hypertensive agents to treat elevated BP</description>
        </group>
        <group group_id="P2">
          <title>Agressive Inhibition of the RAS</title>
          <description>40-80 mg benazepril plus 25-100 mg losartan both p.o. 1-2X per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Noncompliant w/study protocol at &lt;3 mos</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Inhibition of RAS</title>
          <description>10 mg benazepril plus other anti-hypertensive agents to treat elevated BP</description>
        </group>
        <group group_id="B2">
          <title>Agressive Inhibition of the RAS</title>
          <description>40-80 mg benazepril plus 25-100 mg losartan both p.o. 1-2X per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="6.7"/>
                    <measurement group_id="B2" value="51.6" spread="5.9"/>
                    <measurement group_id="B3" value="53.0" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio</title>
        <description>Average of ratio for all participants during the 3-36 months of the study</description>
        <time_frame>3 to 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Inhibition of RAS</title>
            <description>10 mg benazepril plus other anti-hypertensive agents to treat elevated BP</description>
          </group>
          <group group_id="O2">
            <title>Agressive Inhibition of the RAS</title>
            <description>40-80 mg benazepril plus 25-100 mg losartan both p.o. 1-2X per day</description>
          </group>
        </group_list>
        <measure>
          <title>Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio</title>
          <description>Average of ratio for all participants during the 3-36 months of the study</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.1" spread="652.3"/>
                    <measurement group_id="O2" value="376.2" spread="404.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Glomerular Filtration Rate</title>
        <description>This is an average for all participants during the 3-36 month study period</description>
        <time_frame>3 to 36 months</time_frame>
        <population>Completers</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Inhibition of RAS</title>
            <description>10 mg benazepril plus other anti-hypertensive agents to treat elevated BP</description>
          </group>
          <group group_id="O2">
            <title>Agressive Inhibition of the RAS</title>
            <description>40-80 mg benazepril plus 25-100 mg losartan both p.o. 1-2X per day</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Glomerular Filtration Rate</title>
          <description>This is an average for all participants during the 3-36 month study period</description>
          <population>Completers</population>
          <units>ml/min/1.73 meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.7" spread="21.6"/>
                    <measurement group_id="O2" value="100.5" spread="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carotid Artery Intima Thickness</title>
        <description>Thickness of intima of right carotid artery; average of all particpants from 6-36 months of study</description>
        <time_frame>6 to 36 months</time_frame>
        <population>Completers</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Inhibition of RAS</title>
            <description>10 mg benazepril plus other anti-hypertensive agents to treat elevated BP</description>
          </group>
          <group group_id="O2">
            <title>Agressive Inhibition of the RAS</title>
            <description>40-80 mg benazepril plus 25-100 mg losartan both p.o. 1-2X per day</description>
          </group>
        </group_list>
        <measure>
          <title>Carotid Artery Intima Thickness</title>
          <description>Thickness of intima of right carotid artery; average of all particpants from 6-36 months of study</description>
          <population>Completers</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.09"/>
                    <measurement group_id="O2" value="0.72" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelial Dysfunction</title>
        <description>Post hyperemia increase in blood flow - fold increase from before and after occluding BP; values are mean of all participants in 6-36 months of study period.</description>
        <time_frame>6 to 36 months</time_frame>
        <population>complerters</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Inhibition of RAS</title>
            <description>10 mg benazepril plus other anti-hypertensive agents to treat elevated BP</description>
          </group>
          <group group_id="O2">
            <title>Agressive Inhibition of the RAS</title>
            <description>40-80 mg benazepril plus 25-100 mg losartan both p.o. 1-2X per day</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Dysfunction</title>
          <description>Post hyperemia increase in blood flow - fold increase from before and after occluding BP; values are mean of all participants in 6-36 months of study period.</description>
          <population>complerters</population>
          <units>Fold increase</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.5"/>
                    <measurement group_id="O2" value="2.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Inhibition of RAS</title>
          <description>10 mg benazepril plus other anti-hypertensive agents to treat elevated BP</description>
        </group>
        <group group_id="E2">
          <title>Agressive Inhibition of the RAS</title>
          <description>40-80 mg benazepril plus 25-100 mg losartan both p.o. 1-2X per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Systolic BP &lt;100 mm Hg</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mayer B. Davidson, MD</name_or_title>
      <organization>Charles R. Drew University</organization>
      <phone>323 357-3439</phone>
      <email>mayerdavidson@cdrewu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

